




Searching News Database: tumor microenvironment
HSMN NewsFeed - 3 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
HSMN NewsFeed - 15 Feb 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
HSMN NewsFeed - 6 Sep 2023
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
HSMN NewsFeed - 9 Aug 2022
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
HSMN NewsFeed - 29 Jul 2022
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
HSMN NewsFeed - 7 Jul 2022
Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology
Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
HSMN NewsFeed - 10 Aug 2020
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
HSMN NewsFeed - 7 Jul 2020
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
HSMN NewsFeed - 28 Jun 2018
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
HSMN NewsFeed - 23 Aug 2017
Macrophage Pharma Limited Extends Series A Round to Include New Investor Merck Ventures
Macrophage Pharma Limited Extends Series A Round to Include New Investor Merck Ventures
HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 4 Nov 2015
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
HSMN NewsFeed - 21 Sep 2015
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline
HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
HSMN NewsFeed - 7 Apr 2014
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 4 Oct 2013
MetaStat's MetaSite Breast(TM) Diagnostic Assay Predicts Metastasis in Breast Cancer Study
MetaStat's MetaSite Breast(TM) Diagnostic Assay Predicts Metastasis in Breast Cancer Study
HSMN NewsFeed - 13 Sep 2013
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Additional items found! 6

Members Archive contains
6 additional stories matching:
tumor microenvironment
(Password required)
tumor microenvironment
(Password required)